ATXS
Price
$4.06
Change
-$0.02 (-0.49%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
230.25M
28 days until earnings call
ZVRA
Price
$6.57
Change
-$0.28 (-4.09%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
370.15M
28 days until earnings call
Ad is loading...

ATXS vs ZVRA

Header iconATXS vs ZVRA Comparison
Open Charts ATXS vs ZVRABanner chart's image
Astria Therapeutics
Price$4.06
Change-$0.02 (-0.49%)
Volume$18.3K
Capitalization230.25M
Zevra Therapeutics
Price$6.57
Change-$0.28 (-4.09%)
Volume$7.54K
Capitalization370.15M
ATXS vs ZVRA Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. ZVRA commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and ZVRA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (ATXS: $4.08 vs. ZVRA: $6.84)
Brand notoriety: ATXS and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 379% vs. ZVRA: 150%
Market capitalization -- ATXS: $230.25M vs. ZVRA: $370.15M
ATXS [@Biotechnology] is valued at $230.25M. ZVRA’s [@Biotechnology] market capitalization is $370.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • ZVRA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than ZVRA.

Price Growth

ATXS (@Biotechnology) experienced а -26.09% price change this week, while ZVRA (@Biotechnology) price change was -10.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

ZVRA is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZVRA($370M) has a higher market cap than ATXS($230M). ZVRA YTD gains are higher at: -17.986 vs. ATXS (-54.362). ZVRA has higher annual earnings (EBITDA): -76.4M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. ZVRA (69.5M). ATXS has less debt than ZVRA: ATXS (5.35M) vs ZVRA (60.3M). ZVRA has higher revenues than ATXS: ZVRA (23.6M) vs ATXS (0).
ATXSZVRAATXS / ZVRA
Capitalization230M370M62%
EBITDA-111.56M-76.4M146%
Gain YTD-54.362-17.986302%
P/E RatioN/AN/A-
Revenue023.6M-
Total Cash328M69.5M472%
Total Debt5.35M60.3M9%
FUNDAMENTALS RATINGS
ATXS vs ZVRA: Fundamental Ratings
ATXS
ZVRA
OUTLOOK RATING
1..100
7980
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
10074
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
9661
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (63) in the Biotechnology industry is in the same range as ZVRA (84) in the null industry. This means that ATXS’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (74) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (94) in the Biotechnology industry is in the same range as ZVRA (98) in the null industry. This means that ATXS’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Price Growth Rating (61) in the null industry is somewhat better than the same rating for ATXS (96) in the Biotechnology industry. This means that ZVRA’s stock grew somewhat faster than ATXS’s over the last 12 months.

ZVRA's P/E Growth Rating (17) in the null industry is significantly better than the same rating for ATXS (100) in the Biotechnology industry. This means that ZVRA’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSZVRA
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 25 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 7 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DLQAX10.44N/A
N/A
BNY Mellon Large Cap Equity A
FCUIX17.10N/A
N/A
NYLI PineStone U.S. Equity Class I
ISGNX11.82N/A
N/A
Columbia Integrated Small Cap Gr Instl
FATIX100.91N/A
N/A
Fidelity Advisor Technology I
MSTQX11.03N/A
N/A
Morningstar US Equity

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+8.80%
KYMR - ATXS
50%
Loosely correlated
+13.78%
XENE - ATXS
49%
Loosely correlated
+11.73%
TRDA - ATXS
49%
Loosely correlated
+9.14%
DNLI - ATXS
48%
Loosely correlated
+12.12%
IMNM - ATXS
48%
Loosely correlated
+11.69%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with CRNX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+3.79%
CRNX - ZVRA
36%
Loosely correlated
+8.18%
ATXS - ZVRA
36%
Loosely correlated
+8.80%
QURE - ZVRA
36%
Loosely correlated
+9.95%
RVMD - ZVRA
34%
Loosely correlated
+12.82%
KYMR - ZVRA
34%
Loosely correlated
+13.78%
More